Eye fluid clues may unlock why wet AMD treatment fails for some

NCT ID NCT07249216

Recruiting now Knowledge-focused Sponsor: Singapore National Eye Centre Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to find out why 20-40% of people with wet age-related macular degeneration (AMD) don't respond well to standard anti-VEGF injections. Researchers will collect fluid from inside the eye of 117 patients and compare those who respond well to treatment with those who don't. By identifying other molecules involved, they hope to discover new ways to treat or predict poor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ranibizumab
What this could lead to: If successful, this could point toward new treatments or biomarkers for wet AMD patients who don't respond well to current therapy.
What could go wrong: This is an early observational study with only 117 participants, so findings may not apply broadly or lead to immediate new treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Locations

Singapore National Eye Centre/Singapore Eye Research Institute
RECRUITING

Singapore, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.